What is the appropriate management and treatment of peptic ulcer disease?

Management and Treatment of Peptic Ulcer Disease

All patients with peptic ulcer disease should undergo H. pylori testing, and if positive, receive eradication therapy with standard triple therapy (PPI + amoxicillin + clarithromycin) for 14 days in areas of low clarithromycin resistance, as this prevents ulcer recurrence and reduces mortality from complications. 1

Diagnostic Approach

H. pylori Testing

• Test all patients with peptic ulcer disease for H. pylori infection prior to discharge 1
• Use urea breath test (UBT) with 88-95% sensitivity and 95-100% specificity, or stool antigen testing with 94% sensitivity and 92% specificity 1
• In bleeding peptic ulcer, endoscopic tissue biopsy can confirm H. pylori status 1
• Serological tests require local validation with ≥90% sensitivity and specificity; most whole blood tests are inadequate 1
• Delay testing 4-8 weeks after bleeding episodes to avoid false negatives 1

Endoscopy Indications

• Patients above local age cutoff (dependent on gastric cancer incidence) 1
• Presence of alarm symptoms (bleeding, perforation, weight loss, anemia) 1
• Chronic NSAID users 1
• Gastric ulcers require endoscopic follow-up to confirm complete healing and exclude malignancy 1

Treatment Algorithms

H. pylori-Positive Peptic Ulcers

First-Line Therapy (Low Clarithromycin Resistance <20%):

• Standard triple therapy for 14 days 1:
  • PPI standard dose twice daily
  • Clarithromycin 500 mg twice daily
  • Amoxicillin 1000 mg twice daily (or Metronidazole 500 mg twice daily if penicillin allergic)
• Start therapy 72-96 hours after IV PPI administration in bleeding ulcers 1

First-Line Alternative (High Clarithromycin Resistance >20%):

• Sequential therapy for 10 days (if compliance can be maintained) 1:
  • Days 1-5: PPI twice daily + Amoxicillin 1000 mg twice daily
  • Days 6-10: PPI twice daily + Clarithromycin 500 mg twice daily + Metronidazole 500 mg twice daily

Second-Line Therapy (If First-Line Fails):

• Levofloxacin-based triple therapy for 10 days 1:
  • PPI standard dose twice daily
  • Levofloxacin 500 mg once daily (or 250 mg twice daily)
  • Amoxicillin 1000 mg twice daily

Third-Line Therapy:

• Requires H. pylori culture and antibiotic susceptibility testing 1

Acid Suppression Duration

Uncomplicated Duodenal Ulcers:

• No prolonged PPI therapy required after successful H. pylori eradication 1
• Ulcers heal in 80-100% of patients within 4 weeks with acid blockers 2

Gastric Ulcers and Complicated Duodenal Ulcers:

• Continue PPI therapy until complete healing confirmed 1
• Gastric ulcers >2 cm may require 8 weeks of treatment 2
• Endoscopic follow-up mandatory for gastric ulcers to ensure healing 1

Bleeding Peptic Ulcers:

• High-dose IV PPI for 72-96 hours, then transition to oral therapy 1
• Continue PPI until H. pylori eradication confirmed 1

H. pylori-Negative Peptic Ulcers

NSAID-Induced Ulcers:

• Discontinue NSAID if possible - heals 95% of ulcers and reduces recurrence from 40% to 9% 2
• If NSAID cannot be discontinued: PPI therapy (omeprazole or lansoprazole) 2, 3
• Consider switching to lower-risk NSAID (e.g., ibuprofen instead of ketorolac) 2

Idiopathic Ulcers (H. pylori-negative, non-NSAID):

• Full-dose PPI therapy (omeprazole 20 mg once daily) for ulcer-like dyspepsia 1
• Consider prokinetic agents for dysmotility-like symptoms (fullness, bloating) 1

Prevention Strategies

NSAID Users with Ulcer History

• PPIs with or without celecoxib recommended 3
• Vonoprazan (VPZ) suggested as alternative 3
• Misoprostol is alternative option 4

Low-Dose Aspirin Users with Ulcer History

• PPIs or VPZ recommended 3
• H2-receptor antagonists suggested as alternative 3

High-Risk Patients

• Concomitant use of antiplatelet drugs, warfarin, SSRIs, or bisphosphonates increases PUD risk 4
• Primary prophylaxis with PPIs for patients at highest risk 5

Critical Clinical Pitfalls

H. pylori Eradication Timing:

• Do not delay eradication therapy until after discharge - this reduces compliance and increases loss to follow-up 1
• Start treatment immediately after reintroduction of oral feeding in bleeding ulcers 1
• Eradication reduces rebleeding from 26% to 0-2% 1, 2

Antibiotic Resistance:

• Treatment selection must be based on local clarithromycin resistance patterns 1
• Metronidazole resistance limits bismuth triple therapy effectiveness 6

Confirmation of Eradication:

• Mandatory in gastric ulcers and complicated duodenal ulcers 1
• Use UBT or stool antigen test, not serology 1

Complications:

• Bleeding occurs in 73% of complicated cases, perforation in 9%, obstruction in 3% 2
• Early endoscopy with high-dose PPI reduces mortality in bleeding ulcers 5, 7
• Perforation requires immediate surgical intervention 8

Outcomes

• H. pylori eradication decreases ulcer recurrence from 50-60% to 0-2% 2
• Approximately 10,000 annual deaths from PUD in the US 2
• Prompt recognition and treatment improve outcomes, especially in elderly and frail patients 1